The global endoscopic retrograde cholangiopancreatography market size reached US$ 1.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2028, exhibiting a growth rate (CAGR) of 6.7% during 2023-2028.
Endoscopic retrograde cholangiopancreatography (ERCP) is an imaging technique that diagnoses and treats abnormalities in the liver, gallbladder, bile ducts, and pancreas. It combines X-rays and a long, flexible, lightweight endoscope tube that passes through the esophagus, mouth, and stomach. It helps detect blockages, stones, infections, and tumors in the bile duct and fluid leakage from the pancreatic duct. Besides this, it is a less invasive procedure than open surgery and provides more detailed and accurate information about the pancreaticobiliary system. As a result, the demand for endotherapy devices is increasing across the globe to investigate dysphagia, diarrhea, weight loss, heartburn, and stool blood.
The growing global population and the rising prevalence of various chronic gastrointestinal (GI) and incessant biliary medical disorders, including Barrett's disease, biliary, liver, Crohn's, inflammatory bowel, and peptic ulcer disease, and gastroesophageal reflux disorder (GERD), represent one of the key factors positively influencing the market. In addition, the increasing occurrence of benign pancreas and liver tumors, especially among the geriatric population, along with the growing occurrence of cancer across the globe, is driving the market. In line with this, the expansion of hospitals and diagnostic centers is increasing the need for imaging techniques propelling the market growth. Furthermore, rising investments by governments and healthcare organizations of various countries in advanced endoscopy devices and improve endoscopy research is strengthening the market growth. Apart from this, the shifting consumer preference toward minimally invasive surgeries for a speedy recovery and minimal pain and rising awareness about ERCP devices like sphincterotomes are offering a favorable market outlook. Moreover, continuous improvements in healthcare infrastructure and a considerable rise in medical tourism are expected to propel market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global endoscopic retrograde cholangiopancreatographymarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, procedure and end user.
Breakup by Product:
Breakup by Procedure:
Pancreatic Duct Stenting
Pancreatic Duct Dilatation
Breakup by End User:
Hospitals and Clinics
Ambulatory Surgery Centers
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation and Telemed Systems Inc.
Base Year of the Analysis
Product, Procedure, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation and Telemed Systems Inc.
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global endoscopic retrograde cholangiopancreatography market was valued at US$ 1.5 Billion in 2022.
We expect the global endoscopic retrograde cholangiopancreatography market to exhibit a CAGR of 6.7% during 2023-2028.
The rising prevalence of various chronic Gastrointestinal (GI) and incessant biliary medical disorders, along with the increasing consumer preference towards minimally invasive surgeries for a speedy recovery and minimal pain, is primarily driving the global endoscopic retrograde cholangiopancreatography market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective dysphagia, diarrhea, and heartburn treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for endoscopic retrograde cholangiopancreatography.
Based on the product, the global endoscopic retrograde cholangiopancreatography market can be segmented into endoscope, endotherapy devices, visualization systems, energy devices, and others. Currently, endotherapy devices hold the majority of the total market share.
Based on the procedure, the global endoscopic retrograde cholangiopancreatography market has been divided into biliary sphincterotomy, biliary stenting, biliary dilatation, pancreatic sphincterotomy, pancreatic duct stenting, and pancreatic duct dilatation. Among these, biliary sphincterotomy currently exhibits a clear dominance in the market.
Based on the end user, the global endoscopic retrograde cholangiopancreatography market can be categorized into hospitals and clinics, ambulatory surgery centres, and others. Currently, hospitals and clinics account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global endoscopic retrograde cholangiopancreatography market include Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation, and Telemed Systems Inc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.